clinical holds
Untangling Sarepta’s Gene Therapy Fallout and Trust Deficit
Sarepta Therapeutics; gene therapy; Elevidys; Duchenne muscular dystrophy; limb-girdle muscular dystrophy; patient deaths; FDA; AAVrh74 vector; regulatory action; clinical holds; transparency